Elucid

A new JACC Journals: Case Reports publication highlights an important reality in #cardiovascularcare: high-risk coronary disease can be clinically silent. In this case, advanced coronary CT imaging revealed extensive plaque dominated by lipid-rich necrotic core (#LRNC), a key marker of vulnerable plaque and future coronary events. Read here: sciencedirect.com/science/articl… Key takeaways: • Severe coronary disease may exist without symptoms, underscoring the limits of symptom-based detection • LRNC is a critical marker of plaque vulnerability and future risk • Advanced coronary imaging can reveal hidden disease earlier, enabling more proactive management Studies like this reinforce the importance of detecting true disease earlier—before heart attack or stroke occurs. Congrats to the authors! Drs. @elisarrarasx, Robert Pelberg, Jacob S. Roberts, @JayShah_MD, Jeffrey Xia, Sammy Sayed, Norman Lepor, Jairo Aldana-Bitar, @RonKarlsbergMD, Geoffrey Cho #Cardiology #CCTA #CoronaryPlaque #PreventiveCardiology #CardiovascularImaging #CAD

❤️ We’re grateful to support a cause that’s truly close to our hearts, made possible by the continued generosity of the Elucid team. In honor of #AmericanHeartMonth, we’re assembling #BraveryBags for the @MendedHearts community at @BostonChildrens, helping bring comfort to young patients and their families. Moments like this are a powerful reminder of why we do what we do. Taking time to #giveback keeps us grounded in our mission to help physicians improve cardiovascular care. Looking forward to delivering these soon!! 🫶 #TeamElucid #ElucidCares

Check out a podcast i was featured in about coronary artery calcium scanning podcasts.apple.com/us/podcast/292…

🩺 Tune in as Dr. Bon-Kwon Koo, MD, PhD, Professor of Cardiology at Seoul National University walks us through what it takes to truly personalize a patient's treatment plan, combining insights from CT angiography, physiology, and advanced imaging analysis. #yesCCT #plaqueanalysis 👉 Find out more about how Elucid's Plaque-IQ can help support your CT program by visiting elucid.com or by sending us a direct message here! 🫀 Ask us why #histologymatters - Plaque-IQ is the only solution objectively validated against tissue samples, the gold standard for plaque characterization, allowing physicians to measure true disease rather than indirect proxies.

❤️ Heart disease remains the leading cause of death worldwide. During #AmericanHeartMonth, Elucid stands with @American_Heart to raise awareness of the importance of early, personalized cardiovascular care. We're also excited to continue our tradition of supporting @MendedHearts Bravery Bags initiative. Learn more about the program here: mendedhearts.org/treatmentsuppo…

Thank you @MedicalTechMag for an insightful conversation with Kelly Huang, PhD, right on time to kick off American Hearth Month in February! As we all have seen, a major shift in coronary artery disease care is underway. Recent reimbursement decisions for coronary plaque analysis signal a clear move toward more precise plaque-based diagnosis. 🔹 Reimbursement unlocks adoption: With coverage now in place, clinicians can more easily use quantitative plaque analysis to identify high-risk disease sooner. 🔹 With histology-validated Plaque-IQ™, Elucid is helping redefine how coronary disease is detected, managed, and prevented. The future of CAD care is proactive, precise, and plaque-based. Read more: medicaldevice-network.com/news/coronary-… #PrecisionCardiology #PlaqueAnalysis #CardiacImaging #MedTech #HealthcareInnovation #cardiotwitter

🫀 Why is lipid rich necrotic core such a significant marker for risk? See Dr. Jagat Narula's review of plaque characteristics as they relate to acute coronary syndrome, based on overall hierarchical importance of various morphological characteristics of plaque vulnerability. 💡 Ask us how Elucid's Plaque-IQ can uniquely help you identify lipid rich necrotic core from coronary and carotid CT scans. Let's discuss how Plaque-IQ can help your practice detect disease earlier and personalize care to prevent heart attack and stroke. #LRNC #plaqueanalysis #cardiotwitter #cardiovascularcare #yesCCT

🚨 Big news to kick off 2026: elucid.com/elucid-announc… 🔹 A major milestone for coronary plaque analysis Elucid’s Plaque-IQ™ has received a Category I CPT® code (75577) effective January 1, 2026, establishing reimbursement across care settings and recognizing plaque analysis as an essential clinical tool. 🔹 Broad coverage now in place Payors representing 70%+ of covered U.S. lives now have policies covering coronary plaque analysis, accelerating access for physicians and patients. 🔹 Seeing disease at its source Plaque-IQ is the only plaque analysis validated against ground-truth histology, enabling clinicians to identify high-risk plaque and personalize care to help prevent heart attacks and stroke. #Cardiology #CoronaryCTA #PlaqueAnalysis #PrecisionCardiology

Stroke and heart attack often share the same root cause: atherosclerotic plaque. At Elucid, we’re uniquely positioned to offer PlaqueIQ™ for both carotid and coronary anatomies, providing clinicians with a more complete picture of vascular disease risk: 🧠 Carotid plaque analysis to help assess stroke risk 🫀 Coronary plaque analysis to help identify patients at risk for coronary artery disease and heart attack Ask our team about how our histology-based technology, trained on real plaque tissue, not just imaging proxies, presents a unified, biology-driven approach to identifying high-risk plaque... wherever it lives. #StrokePrevention #HeartHealth #CardiovascularDisease #Atherosclerosis #PlaqueAnalysis

A meaningful milestone for coronary artery disease #CAD assessment: With the introduction of Category I CPT® Code 75577, advanced coronary plaque analysis like PlaqueIQ™ is now formally recognized as part of standard clinical care. For Elucid, this moment underscores the growing importance of histology-based plaque characterization, grounded in years of pathology correlation. By identifying and quantifying plaque types associated with disease activity and risk, this approach gives clinicians deeper insight into the biology of atherosclerosis, not just its presence. #histologymatters Category I designation represents progress for the field and, most importantly, broader access to data-driven, personalized cardiovascular care for patients. We look forward to continued momentum in 2026 as plaque analysis plays an increasingly central role in guiding prevention, treatment, and outcomes in coronary care. #cardiotwitter

This holiday season, we’re grateful for the clinicians, researchers, and partners who have joined us on the mission to conquer cardiovascular disease together… one plaque at a time. #histologymatters Happy and safe holidays, and warm wishes from all of us at Elucid!

Tune in as Dr. Amir Ahmadi @amir_ahmadi__ discusses the MI Paradox: the majority of myocardial infarction comes from populations of low/intermediate risk who are non-ischemic and non-symptomatic, but the current cardiology framework targets risk factors and symptoms. Recent data shows that a risk calculators are missing far too many at-risk patients. In fact, nearly half of people who suffer a first heart attack would not have qualified for preventive therapy under current ASCVD or PREVENT risk models — and most had no warning symptoms before their event. Watch more here: youtu.be/PyeAK-r3gas?si… #yescct #ctfirst #preventivecare

Pt 2: From our recent webinar hosted by @Heart_SCCT, Dr. Rasha Al-Lamee highlights some key strategies recommended by the Lancet Commission on #CoronaryArteryDisease: 1. Shifting the focus to #atheroma 2. Reassessing the impact of CAD prevention from a younger age 3. Developing new strategies for prevention and treatment Watch the rest of the webinar here: youtu.be/PyeAK-r3gas?si… #globalhealth #preventivecare #cardiovasculardisease

🎤 We loved speaking with Dr. Anna S. Mueller about the future of cardiac CT and the growing importance of incorporating cardiac CT and plaque analysis early in the patient care pathway. 🩺 Her insights on how personalized imaging can influence patient behavior (including improved medication adherence!) highlight the real-world impact of precision cardiovascular care. Thank you, Dr. Mueller, for sharing your perspective and for helping move the field toward better long-term outcomes through data-driven decision making. Read the recent publication from Dr. Mueller & team that's been making waves in the news: sciencedirect.com/science/articl… #CardiacCT #CCTA #PlaqueAnalysis #Cardiology #PrecisionMedicine #PreventiveCare

Revisit Dr. Rasha Al-Lamee's presentation on the #globalhealth burden of coronary artery disease from our recent webinar hosted by @Heart_SCCT. The trajectory of mortality rates, prevalence, and financial burden are all rising in the coming years - stay tuned to hear how the Lancet Commission hopes to tackle the issue. Watch the entire webinar here: youtu.be/PyeAK-r3gas?si… #Cardiology #CCTA #PlaqueAnalysis #PrecisionMedicine #Atherosclerosis

New CPT I Code, OPPS and MPFS decisions recognize significant clinical value of plaque analysis technologies like PlaqueIQ across care settings - read the latest at elucid.com: “The CY 2026 CMS final rules are great news for clinicians and their patients who will now have broad access to innovative, evidence-based imaging tools that help identify high-risk cardiovascular individuals earlier and more accurately,” said Elucid’s CEO Kelly Huang, PhD. #plaqueanalysis #CMS #cardiovascularhealth

Happy Thanksgiving to all. At Elucid, we are grateful every day for our incredible team, our partners and supporters who believe in our mission, and the dedicated healthcare professionals working tirelessly to prevent heart attacks and improve cardiovascular outcomes for patients everywhere. Thank you for inspiring us to push boundaries and make a meaningful impact. Wishing you and your loved ones a safe, joyful, and heart-healthy #Thanksgiving.

🦃 Got plans after Thanksgiving? Find us at #RSNA2025 - or make an appointment in advance! Ask us how Elucid makes a difference in the imaging world to prevent heart attacks and strokes. 🔎 Elucid's PlaqueIQ, powered by CT Virtual Histology, is the only FDA-approved software indicated for coronary and carotid arteries 🫀 🧠 Meet us at RSNA to learn more about our histology-validated plaque analysis. Visit elucid.com for more info. #cardiacimaging #neuroimaging